EGFR and head and neck squamous cell carcinoma: Notably, similarly to MAGEAs, EGFR, an important therapeutic target in HNSCC, is highly expressed in tumors distant to the normal phenotype, defining the groups of patients that could benefit from EGFR-inhibitors [31].